# Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

> **NCT07646301** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 103 (estimated)

## Conditions studied

- Uterine Cervical Neoplasms
- Locally Advanced

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT07646301
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646301, "Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07646301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*